Form D · Biotechnology
CereVasc, Inc.
Auburndale, MA · CIK 0001814258
Offering snapshot reported Jun 5, 2020 · SEC filing
- Reported sold
- $11.1M Offering amount: $32.5M
- Investors reported
- 5 Form D · investor count
- Minimum accepted
- $0 Reported outside-investor minimum
- First sale
- May 22, 2020 As reported in this filing
What changed?
Latest filing versus its linked predecessor, where available.
No comparable changes in the displayed metrics.
Filing history
Scroll to see all columns →
| Filed | Filing type | Reported sold | Change vs linked filing | Investors | Source |
|---|---|---|---|---|---|
| Jun 5, 2020 | Initial | $11,052,975 | No comparison | 5 | SEC filing |
Offering details
- Securities
- Equity
- Exemptions
- 06b
- Duration over one year
- Yes
- Business combination
- No
- Sales commissions
- $0
- Finders' fees
- $0
- Form D file number
- 021-368402
Source: Form D, filed Jun 5, 2020. Minimum accepted may differ from a standard advertised minimum.
Fund connections
No confirmed ADV fund connection is available for this issuer.
People & organizations
Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.
| Name | Reported role |
|---|---|
| Frederick Callori | Director |
| Chris Garabedian | Director |
| Carl Heilman | Director |
| Aaron Levangie | Executive |
| Daniel Levangie | Director, Executive |
| Patrick Sullivan | Director |
| Leslie Teso Lichtman | Executive |
Issuer details
Industry: Biotechnology (See others in industry)
Address:
2120 Commonwealth Ave., Suite 1
Auburndale, MA, 02466
Auburndale, MA, 02466